Preemptive Pharmacogenomics

Preemptive Pharmacogenomics is a pharmacogenomic strategy that involves the prospective genotyping of individuals for drug response-related genetic variants prior to the onset of therapy, in order to guide future medication selection and dosing.

16

Publications

1.9K

Citations

346

Authors

88

Institutions

Publications per year

2017–2026

4

Publications

16

1–5 of 16

Authors

346

  1. SJ
    Suzette J. Bielinski

    Mayo Clinic in Florida, United States

    4 publications · 812 citations

    4

    h-index

  2. RM
    Richard M. Weinshilboum

    Mayo Clinic, United States

    3 publications · 568 citations

    3

    h-index

  3. RR
    Robert R. Freimuth

    Mayo Clinic, United States

    3 publications · 581 citations

    3

    h-index

  4. JL
    John L. Black

    Mayo Clinic, United States

    3 publications · 568 citations

    3

    h-index

  5. JM
    Jennifer M. Skierka

    Mayo Clinic, United States

    3 publications · 568 citations

    3

    h-index

1–5 of 346

Venues

  1. Clinical Pharmacology & Therapeutics

    CPT · 5 publications · 786 citations

    5

    h-index

  2. Frontiers in Pharmacology

    1 publications · 45 citations

    1

    h-index

  3. Journal of Psychiatric Research

    1 publications · 36 citations

    1

    h-index

  4. Pharmacogenetics and Genomics

    1 publications · 43 citations

    1

    h-index

  5. Drug Discovery Today

    1 publications · 64 citations

    1

    h-index

1–5